Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin

Familial Cancer

Volumn 8, Issue 1, 2009, Pages 29-32

  Kadouri, Luna ^a   Temper, Mark ^a   Grenader, Tal ^a   Abeliovich, Dvorah ^b   Hamburger, Tamar ^a   Peretz, Tamar ^a   Lotem, Michal ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Ashkenazi; BRCA1; BRCA2; Melanoma; Risk

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CANCER; PRIORITY JOURNAL;

BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JEWS; MALE; MELANOMA; MUTATION; POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

EID: 59449090970     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-008-9206-8     Document Type: Article

References (25)

1. S Stahl E Bar-Meir E Friedman 2004 Genetics of melanoma Isr Med Assoc J 6 774 777
2. The Breast Cancer Linkage Consortium 1999 Cancer risks in BRCA2 mutation carriers J Natl Cancer Inst 91 1310 1316 10.1093/jnci/91.15.1310
3. DF Easton L Steele P Fields 1997 Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13 Am J Hum Genet 61 120 128 10.1086/513891
4. MS Brose TR Rebbeck KA Calzone 2002 Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program J Natl Cancer Inst 94 1365 1372
5. D Thompson DF Easton 2002 The Breast Cancer Linkage Consortium cancer incidence in BRCA1 mutation carriers J Natl Cancer Inst 94 1358 1365
6. JP Struewing P Hartge S Wacholder 1997 The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1401 1408 10.1056/NEJM199705153362001
7. CB Begg 2002 On the use of familial aggregation in population based case probands for calculating penetrance J Natl Cancer Inst 94 1221 1226
8. SB Gruber GM Petersen 2002 Cancer risks in BRCA1 carriers: time for the next generation of studies J Natl Cancer Inst 94 1344 1345
9. BL Niell G Rennert JD Bonner 2004 BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer J Natl Cancer Inst 96 15 21
10. O Yossepowitch N Olvera JM Satagopan 2003 BRCA1 and BRCA2 germline mutations in lymphoma patients Leuk Lymphoma 44 127 131 10.1080/ 1042819021000040332
11. A Hubert T Peretz O Manor 1999 The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer Am J Hum Genet 65 921 924 10.1086/302525
12. CM Phelan E Kwan E Jack 2002 A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families Hum Mutat 20 352 357 10.1002/humu.10123
13. J Iscovich M Abdulrazik C Cour 2002 Prevalence of BRCA2 6174delT mutation in Israeli uveal melanoma patients Int J Cancer 98 42 44 10.1002/ijc.10155
14. N Hearle BE Damato J Humphreys 2003 Contribution of germline mutations in BRCA2, P16 (INK4A), P14 (ARF) and P15 to uveal melanoma Invest Ophthalmol Vis Sci 44 458 462 10.1167/iovs.02-0026
15. MT Landi AM Goldstein S Tsang 2004 Genetic susceptibility in familial melanoma from northeastern Italy J Med Genet 41 557 566 10.1136/jmg.2003.016907
16. W Goggins W Gao H Tsao 2004 Association between female breast cancer and cutaneous melanoma Int J Cancer 111 792 794 10.1002/ijc.20322
17. K Hemminki P Vaittinen D Easton 2000 Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes Int J Cancer 88 87 91 10.1002/1097-0215(20001001)88:1 ≤ 87::AID-IJC14 ≥ 3.0.CO;2-F
18. HS Evans CM Lewis D Robinson 2001 Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility Int J Cancer 94 758 759 10.1002/ijc.1534
19. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711-719 doi: 10.1136/jmg.2004.028829
20. J Lubinski CM Phelan P Ghadirian 2004 Cancer variation associated with the position of the mutation in the BRCA2 gene Fam Cancer 3 1 10 10.1023/B:FAME.0000026816.32400.45
21. L Kadouri DF Easton S Edwards 2001 CAG and GGC repeat polymorphism in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers Br J Cancer 85 36 40 10.1054/bjoc.2001.1777
22. L Kadouri Z Kote-Jarai A Hubert 2004 A single nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 but not in BRCA1 carriers or non-carriers Br J Cancer 90 2002 2005 10.1038/sj.bjc.6601837
23. L Kadouri Z Kote-Jarai EF Easton 2004 Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers Int J Cancer 108 399 403 10.1002/ijc.11531
24. SC Wang K Makino LK Su AY Pao JS Kim MC Hung 2001 Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway Cancer Res 61 2838 2842
25. S Galper R Gelman A Recht B Silver A Kohli JS Wong 2002 Second non-breast malignancies after conservative surgery and radiation therapy for early-stage breast cancer Int J Radiat Oncol Biol Phys 52 406 414 10.1016/S0360-3016(01) 02661-X